Pasar al contenido principal

PROTEINAS DE UNION AL ARN EN LA ETIOLOGIA DE LA ENFERMEDAD DE HUNTINGTON Y OTRAS PATOLOGIAS NEURALES

RTI2018-096322-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Altered levels and isoforms of Tau and nuclear membrane invaginations in Huntington's disease

  • Fernández-Nogales, Marta
  • Lucas, José Javier
Since the early reports of neurofibrillary Tau pathology in brains of some Huntington's disease (HD) patients, mounting evidence of multiple alterations of Tau in HD brain tissue has emerged in recent years. Such Tau alterations range from increased total levels, imbalance of isoforms generated by alternative splicing (increased 4R-/3R-Tau ratio) or by post-translational modifications such as hyperphosphorylation or truncation. Besides, the detection in HD brains of a new Tau histopathological hallmark known as Tau nuclear rods (TNRs) or Tau-positive nuclear indentations (TNIs) led to propose HD as a secondary Tauopathy. After their discovery in HD brains, TNIs have also been reported in hippocampal neurons of early Braak stage AD cases and in frontal and temporal cortical neurons of FTD-MAPT cases due to the intronic IVS10+16 mutation in the Tau gene (MAPT) which results in an increased 4R-/3R-Tau ratio similar to that observed in HD. TNIs are likely pathogenic for contributing to the disturbed nucleocytoplasmic transport observed in HD. A key question is whether correction of any of the mentioned Tau alterations might have positive therapeutic implications for HD. The beneficial effect of decreasing Tau expression in HD mouse models clearly implicates Tau in HD pathogenesis. Such beneficial effect might be exerted by diminishing the excess total levels of Tau or specifically by diminishing the excess 4R-Tau, as well as any of their downstream effects. In any case, since gene silencing drugs are under development to attenuate both Huntingtin (HTT) expression for HD and MAPT expression for FTD-MAPT, it is conceivable that the combined therapy in HD patients might be more effective than HTT silencing alone., CiberNed-ISCIII collaborative grants 2013/09-2, 2015-2/06 and 2018/06-5 to JL and by grants from Spanish Ministry of Science, Innovation, and Universities (MICINN): SAF2015-65371-R and RTI2018-096322-B-I00 to JL, by the European Union FEDER funds, the Fundación Botín by the Banco Santander through its Santander Universities Global Division and by Fundación Ramón Areces and Fundación Alicia Koplowitz
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism

  • Hernández, Ivó H.
  • Cabrera, Jorge Rubén
  • Santos-Galindo, María
  • Sánchez-Martín, Manuel A.
  • Domínguez, Verónica
  • García-Escudero, Ramón
  • Pérez-Álvarez, María José
  • Pintado, Belén
  • Lucas, José Javier
The Author(s) (2020)., Huntington’s disease and X-linked dystonia parkinsonism are two monogenic basal ganglia model diseases. Huntington’s disease is caused by a polyglutamine-encoding CAG repeat expansion in the Huntingtin (HTT) gene leading to several toxic interactions of both the expanded CAG-containing mRNA and the polyglutamine-containing protein, while X-linked dystonia parkinsonism is caused by a retrotransposon insertion in the TAF1 gene, which decreases expression of this core scaffold of the basal transcription factor complex TFIID. SRSF6 is an RNA-binding protein of the serine and arginine-rich (SR) protein family that interacts with expanded CAG mRNA and is sequestered into the characteristic polyglutamine-containing inclusion bodies of Huntington’s disease brains. Here we report decreased levels of the SRSF6 interactor and regulator SREK1—another SR protein involved in RNA processing—which includes TAF1 as one of its targets. This led us to hypothesize that Huntington’s disease and X-linked dystonia parkinsonism pathogeneses converge in TAF1 alteration. We show that diminishing SRSF6 through RNA interference in human neuroblastoma cells leads to a decrease in SREK1 levels, which, in turn, suffices to cause diminished TAF1 levels. We also observed decreased SREK1 and TAF1 levels in striatum of Huntington’s disease patients and transgenic model mice. We then generated mice with neuronal transgenic expression of SREK1 (TgSREK1 mice) that, interestingly, showed transcriptomic alterations complementary to those in Huntington’s disease mice. Most importantly, by combining Huntington’s disease and TgSREK1 mice we verify that SREK1 overexpression corrects TAF1 deficiency and attenuates striatal atrophy and motor phenotype of Huntington’s disease mice. Our results therefore demonstrate that altered RNA processing upon SREK1 dysregulation plays a key role in Huntington’s disease pathogenesis and pinpoint TAF1 as a likely general determinant of selective vulnerability of the striatum in multiple neurological disorders., This work was supported by CIBERNED-ISCIII collaborative grants PI2015-2/06-3 and PI2018/06-1 and by grants from Spanish Ministry of Economy and Competitiveness/Ministry of Science, Innovation and Universities (MINECO/MCIU/AEI/FEDER, UE): SAF2015-65371-R and RTI2018-096322-B-I00 to J.J.L. and PI18/00263 from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness)—cofunded by the European Regional Development Fund—to R.G.-E. and by institutional grant from Fundación Ramón Areces to CBMSO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease

  • Picó, Sara
  • Parras, Alberto
  • Santos-Galindo, María
  • Pose-Utrilla, Julia
  • Castro, Margarita
  • Fraga, Enrique
  • Hernández, Ivó H.
  • Elorza, Ainara
  • Anta, Héctor
  • Wang, Nan
  • Martí-Sánchez, Laura
  • Belloc, Eulàlia
  • García-Esparcia, Paula
  • Garrido, Juan J.
  • Ferrer, Isidro
  • Macías García, Daniel
  • Mir, Pablo
  • Artuch, Rafael
  • Pérez, Belén
  • Hernández, Félix
  • Navarro, Pilar
  • López-Sendón, José Luis
  • Iglesias, Teresa
  • Yang, X. William
  • Méndez, Raúl
  • Lucas, José Javier
Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the basal ganglia for which disease-modifying treatments are not yet available. Although gene-silencing therapies are currently being tested, further molecular mechanisms must be explored to identify druggable targets for HD. Cytoplasmic polyadenylation element binding proteins 1 to 4 (CPEB1 to CPEB4) are RNA binding proteins that repress or activate translation of CPE-containing transcripts by shortening or elongating their poly(A) tail. Here, we found increased CPEB1 and decreased CPEB4 protein in the striatum of patients and mouse models with HD. This correlated with a reprogramming of polyadenylation in 17.3% of the transcriptome, markedly affecting neurodegeneration-associated genes including PSEN1, MAPT, SNCA, LRRK2, PINK1, DJ1, SOD1, TARDBP, FUS, and HTT and suggesting a new molecular mechanism in neurodegenerative disease etiology. We found decreased protein content of top deadenylated transcripts, including striatal atrophy–linked genes not previously related to HD, such as KTN1 and the easily druggable SLC19A3 (the ThTr2 thiamine transporter). Mutations in SLC19A3 cause biotin-thiamine–responsive basal ganglia disease (BTBGD), a striatal disorder that can be treated with a combination of biotin and thiamine. Similar to patients with BTBGD, patients with HD demonstrated decreased thiamine in the cerebrospinal fluid. Furthermore, patients and mice with HD showed decreased striatal concentrations of thiamine pyrophosphate (TPP), the metabolically active form of thiamine. High-dose biotin and thiamine treatment prevented TPP deficiency in HD mice and attenuated the radiological, neuropathological, and motor HD-like phenotypes, revealing an easily implementable therapy that might benefit patients with HD., This work was supported by CIBERNED-ISCIII collaborative grants 2013/09-2 to J.J.L. and 2015-2/06 and 2018/06-5 to J.J.L. and T.I., grants SAF2015-65371-R (MINECO/AEI/FEDER, UE), and grants from the Spanish Ministry of Science, Innovation and Universities (MINECO/MICINN): RTI2018-096322-B-I00 (MCIU/AEI/FEDER, UE) to J.J.L., SAF2017-88885-R (MINECO/AEI/FEDER, UE) to T.I., BFU2014-54122-P (MINECO/AEI/FEDER, UE) to R.M., and ISCIII-FEDER (PI17/00199; PI20/00625) to P.N. This work was also supported by the European Union FEDER funds, Fundación Botín–Banco Santander through its Santander Universities Global Division and Fundación Ramón Areces. A.P. and S.P. were recipients of FPI fellowships from MICINN/MINECO. A.P. was also hired through CIBERNED. J.P.-U. was contracted by SAF2017-88885-R (MINECO/AEI/FEDER, UE). D.M.-G. was supported by the “Río Hortega” programme (CM18/00142) from ISCIII-FEDER. A.E. was a recipient of Juan de la Cierva contracts from MICINN/MINECO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington¿s disease

  • Picó, Sara
  • Parras, Alberto
  • Santos-Galindo, María
  • Pose-Utrilla, Julia
  • Castro, Margarita
  • Fraga, Enrique
  • Hernández Hernández, Ivo
  • Elorza, Ainara
  • Anta, Héctor
  • Wang, Nan
  • Martí-Sánchez, Laura
  • Belloc, Eulàlia
  • García-Esparcia, Paula
  • Garrido Jurado, Juan José
  • Ferrer, Isidro
  • Macías García, Daniel
  • Mir, Pablo
  • Artuch, Rafael
  • Pérez, Belén
  • Hernández, Félix
  • Navarro Medrano, Pilar
  • López-Sendón, José Luis
  • Iglesias, Teresa
  • Yang, Willian
  • Méndez, Raúl
  • Lucas, José Javier
Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the basal ganglia for which disease-modifying treatments are not yet available. Although gene-silencing therapies are currently being tested, further molecular mechanisms must be explored to identify druggable targets for HD. Cytoplasmic polyadenylation element binding proteins 1 to 4 (CPEB1 to CPEB4) are RNA binding proteins that repress or activate translation of CPE-containing transcripts by shortening or elongating their poly(A) tail. Here, we found increased CPEB1 and decreased CPEB4 protein in the striatum of patients and mouse models with HD. This correlated with a reprogramming of polyadenylation in 17.3% of the transcriptome, markedly affecting neurodegeneration-associated genes including PSEN1, MAPT, SNCA, LRRK2, PINK1, DJ1, SOD1, TARDBP, FUS, and HTT and suggesting a new molecular mechanism in neurodegenerative disease etiology. We found decreased protein content of top deadenylated transcripts, including striatal atrophy–linked genes not previously related to HD, such as KTN1 and the easily druggable SLC19A3 (the ThTr2 thiamine transporter). Mutations in SLC19A3 cause biotin-thiamine–responsive basal ganglia disease (BTBGD), a striatal disorder that can be treated with a combination of biotin and thiamine. Similar to patients with BTBGD, patients with HD demonstrated decreased thiamine in the cerebrospinal fluid. Furthermore, patients and mice with HD showed decreased striatal concentrations of thiamine pyrophosphate (TPP), the metabolically active form of thiamine. High-dose biotin and thiamine treatment prevented TPP deficiency in HD mice and attenuated the radiological, neuropathological, and motor HD-like phenotypes, revealing an easily implementable therapy that might benefit patients with HD., This work was supported by CiberNed-ISCIII collaborative grants 2013/09-2 to J.J.L, 2015-2/06 and 2018/06-5 to J.J.L and T.I., and by grants SAF2015-65371-R (MINECO/AEI/FEDER, UE) and by grants from Spanish Ministry of Science, Innovation and Universities (MINECO/MICINN): RTI2018-096322-B-I00 (MCIU/AEI/FEDER, UE) to J.J.L., SAF2017- 88885-R (MINECO/AEI/FEDER, UE) to T.I., BFU2014-54122-P (MINECO/AEI/FEDER, UE) to R.M., and ISCIII-FEDER (PI17/00199) to P.N., by the European Union FEDER funds, the Fundación Botín by the Banco Santander through its Santander Universities Global Division, by Fundación BBVA and by Fundación Ramón Areces. A.P. and S.P. were recipients of FPI fellowships from MICINN/MINECO, A.P. was also recipient of a contract from CIBERNED, J.P.U. was contracted by SAF2017-88885-R (MINECO/AEI/FEDER, UE), D.M-G. was supported by the “Río Hortega” programme [CM18/00142] from ISCIII-FEDER, A.E. was recipient of Juan de la Cierva contracts from MICINN/MINECO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease

  • Yu, Dahyun
  • Zarate, Nicole
  • White, Angel
  • Coates, De’jah
  • Tsai, Wei
  • Nanclares, Carmen
  • Cuccu, Francesco
  • Yue, Johnny S.
  • Brown, Taylor G.
  • Mansky, Rachel H.
  • Jiang, Kevin
  • Kim, Hyuck
  • Nichols-Meade, Tessa
  • Larson, Sarah N.
  • Gundry, Katherine
  • Zhang, Ying
  • Tomas-Zapico, Cristina
  • Lucas, Jose J.
  • Benneyworth, Michael
  • Öz, Gülin
  • Cvetanovic, Marija
  • Araque, Alfonso
  • Gomez-Pastor, Rocio
Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene for which no therapies are available. HTT mutation causes protein misfolding and aggregation, preferentially affecting medium spiny neurons (MSNs) of the basal ganglia. Transcriptional perturbations in synaptic genes and neuroinflammation are key processes that precede MSN dysfunction and motor symptom onset. Understanding the interplay between these processes is crucial to develop effective therapeutic strategies to treat HD. We investigated the role of protein kinase CK2α’, a kinase upregulated in MSNs in HD and previously associated with Parkinson’s disease (PD), in the regulation of neuroinflammation and synaptic function in HD. We used the heterozygous knock-in zQ175 HD mouse model and compared that to zQ175 mice lacking one allele of CK2α’ (zQ175:CK2α’). CK2α’ haploinsufficiency in zQ175 mice resulted in decreased levels of pro-inflammatory cytokines, HTT aggregation, astrogliosis and transcriptional alterations of synaptic genes related to glutamatergic signaling. zQ175:CK2α’ mice also presented increased frequency of striatal miniature excitatory postsynaptic currents (mEPSCs), an indicator of synaptic activity, and improved motor coordination compared to zQ175 mice. Neuropathological and phenotypic changes mediated by CK2α’ were connected to alpha-synuclein (α-syn) dysregulation and correlated with differences in α-syn serine 129 phosphorylation (pS129-α-syn), a post-translational modification involved in α-synucleinopathy and shown to be regulated by CK2 in PD. pS129-α-syn was increased in the nuclei of MSNs in zQ175 mice and in the striatum of patients with HD, and it decreased in zQ175:CK2α’ mice. Collectively, our data established a novel connection between CK2α’, neuroinflammation and synaptic gene dysregulation with synucleinopathy in HD and suggested common molecular mechanisms of neurodegeneration between HD and PD. Our results also support CK2α’ inhibition as a potential therapeutic strategy to modulate neuronal function and neuroprotection in HD., This work was supported by the Biomedical Research Awards for Interdisciplinary New Science BRAINS (to R.G.P) and the National Institute of Health NINDS (R01 NS110694-01A1) (to R.G.P). The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and the W.M. Keck Foundation. F.C. was supported by the GLOBUS Placement program. National Institute of Health NINDS (R01 NS197387) (to M.C.) and National Institute of Health NINDS R01 MH119355 and R01 NS108686 (to A.A). Grants from Fundación Ramón Areces, MICINN (SAF2009-08233) and MCIU/AEI/FEDER-UE (RTI2018-096322-B-100) to JJL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Prion-associated neurodegeneration causes both endoplasmic reticulum stress and proteasome impairment in a murine model of spontaneous disease

  • Otero, Alicia
  • Betancor, Marina
  • Eraña, Hasier
  • Fernández Borges, Natalia
  • Lucas, José Javier
  • Badiola, Juan José
  • Castilla, Joaquín
  • Bolea, Rosa
Prion diseases are a group of neurodegenerative disorders that can be spontaneous, familial or acquired by infection. Conversion of prion protein PrPC to its abnormal and misfolded isoform PrPSc is the main event in the pathogenesis of prion diseases of all origins. In spontaneous prion diseases, the mechanisms that trigger the formation of PrPSc in the central nervous system, remain unknown. Several reports have demonstrated that the accumulation of PrPSc can induce endoplasmic reticulum (ER) stress and proteasome impairment from early stages of the prion disease. Both mechanisms lead to an increment of PrP aggregates in the secretory pathway, which could explain the pathogenesis of spontaneous prion diseases. Here, we investigate the role of ER stress and proteasome impairment during prion disorders in a murine model of spontaneous prion disease (TgVole) coexpressing the UbG76V-GFP reporter, which allows measuring the proteasome activity in vivo. Spontaneously prion-affected mice showed a significantly higher accumulation of the PKR-like ER kinase (PERK), the ER chaperone binding immunoglobulin protein (BiP/Grp78), the ER protein disulfide isomerase (PDI) and the UbG76V-GFP reporter than age-matched controls in certain brain areas. Upregulation of PERK, BiP, PDI and ubiquitin was detected from the preclinical stage of the disease, indicating that ER stress and proteasome impairment begin at early stages of the spontaneous disease. Strong correlations were found between the deposition of these markers and neuropathological markers of prion disease in both preclinical and clinical mice. Our results suggest that both ER stress and proteasome impairment occur during the pathogenesis of spontaneous prion diseases.